JP2017501202A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501202A5
JP2017501202A5 JP2016544410A JP2016544410A JP2017501202A5 JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5 JP 2016544410 A JP2016544410 A JP 2016544410A JP 2016544410 A JP2016544410 A JP 2016544410A JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5
Authority
JP
Japan
Prior art keywords
nicotinamide
pyridin
cyano
fluoro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501202A (ja
JP6475252B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/010006 external-priority patent/WO2015103453A1/en
Publication of JP2017501202A publication Critical patent/JP2017501202A/ja
Publication of JP2017501202A5 publication Critical patent/JP2017501202A5/ja
Application granted granted Critical
Publication of JP6475252B2 publication Critical patent/JP6475252B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544410A 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物 Expired - Fee Related JP6475252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03
US61/923,403 2014-01-03
PCT/US2015/010006 WO2015103453A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds

Publications (3)

Publication Number Publication Date
JP2017501202A JP2017501202A (ja) 2017-01-12
JP2017501202A5 true JP2017501202A5 (enExample) 2018-12-13
JP6475252B2 JP6475252B2 (ja) 2019-02-27

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544410A Expired - Fee Related JP6475252B2 (ja) 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物

Country Status (21)

Country Link
US (1) US9169252B2 (enExample)
EP (1) EP3089973B1 (enExample)
JP (1) JP6475252B2 (enExample)
KR (1) KR20160101191A (enExample)
CN (1) CN106061967B (enExample)
AR (1) AR098991A1 (enExample)
AU (1) AU2015204045A1 (enExample)
CA (1) CA2935329A1 (enExample)
CL (1) CL2016001706A1 (enExample)
EA (1) EA201691343A1 (enExample)
ES (1) ES2804707T3 (enExample)
IL (1) IL246474A0 (enExample)
MA (1) MA39162A1 (enExample)
MX (1) MX2016008723A (enExample)
PE (1) PE20161292A1 (enExample)
PH (1) PH12016501164A1 (enExample)
SG (1) SG11201605340QA (enExample)
TN (1) TN2016000271A1 (enExample)
TW (1) TW201609693A (enExample)
UY (1) UY35935A (enExample)
WO (1) WO2015103453A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616812T3 (es) 2012-11-08 2017-06-14 Bristol-Myers Squibb Company Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
PE20150953A1 (es) 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
HUE050761T2 (hu) 2014-01-01 2021-01-28 Medivation Tech Llc Vegyületek és alkalmazási eljárások
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10618903B2 (en) 2015-06-24 2020-04-14 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
UY36747A (es) * 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
AR105113A1 (es) 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
US11130756B2 (en) * 2017-08-04 2021-09-28 Bristol-Myers Squibb Company [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds
MY202326A (en) 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3752504A4 (en) 2018-02-14 2021-06-09 Dana Farber Cancer Institute, Inc. IRAQ DEGRADER AND USES THEREOF
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
MX2021015995A (es) 2019-06-28 2022-03-11 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN114174279B (zh) 2019-08-06 2024-07-02 百时美施贵宝公司 可用作irak4抑制剂的双环杂环化合物
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN115052627A (zh) 2019-12-17 2022-09-13 凯麦拉医疗公司 Irak降解剂和其用途
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN115335380B (zh) 2020-02-03 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的三环杂芳基化合物
US12528814B2 (en) 2020-02-19 2026-01-20 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CA3202360A1 (en) 2020-12-30 2022-07-07 Nello Mainolfi Irak degraders and uses thereof
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
CA3207049A1 (en) 2021-02-15 2022-08-18 Jared Gollob Irak4 degraders and uses thereof
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
KR20230019396A (ko) * 2021-07-29 2023-02-08 프라비바이오 주식회사 신규 벤젠 유도체 및 이의 면역억제 관련 용도
WO2023023255A1 (en) 2021-08-18 2023-02-23 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2025151602A1 (en) * 2024-01-11 2025-07-17 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
WO2025151728A1 (en) * 2024-01-12 2025-07-17 Bristol-Myers Squibb Company Ligand directed degrader of irak4
CN118388401B (zh) * 2024-06-28 2024-08-20 成都凯斯坦生物医药有限公司 一种4-氨基-2-氯烟醛的制备方法
CN118641677B (zh) * 2024-08-16 2024-11-05 北京京丰制药集团有限公司 尼可刹米原料中杂质的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
JP4529685B2 (ja) 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類
WO2005007646A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2008258508A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
AU2009320683B2 (en) * 2008-11-28 2012-07-19 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
WO2012149567A1 (en) 2011-04-29 2012-11-01 Mount Sinai School Of Medicine Kinase inhibitors
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
WO2013106612A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
EP2802577B1 (en) 2012-01-13 2017-03-01 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
US9242976B2 (en) 2012-01-13 2016-01-26 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
ES2616812T3 (es) * 2012-11-08 2017-06-14 Bristol-Myers Squibb Company Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
WO2014074660A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
PE20150953A1 (es) * 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa

Similar Documents

Publication Publication Date Title
JP2017501202A5 (enExample)
JP6475252B2 (ja) ヘテロアリール置換のニコチンアミド化合物
JP2018522859A5 (enExample)
JP7576552B2 (ja) イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
AU2011240808B2 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
AU2010333804B2 (en) Fused heteroaromatic pyrrolidinones as syk inhibitors
CN111372931B (zh) 作为蛋白激酶抑制剂的杂环化合物
KR102319857B1 (ko) P2x7 조절제
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP6689871B2 (ja) Fgfr阻害剤としての二環式複素環
AU2017378943A1 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
JP2016523911A5 (enExample)
TW201326173A (zh) 5,7-經取代之-咪唑并[1,2-c]嘧啶
AU2010335556A1 (en) Imidazopyridine derivatives as JAK inhibitors
JP2018524331A5 (enExample)
RS54823B1 (sr) Derivati piperidin-4-il azetidina kao inhibitori jak1
JP2015527399A5 (enExample)
JP2023510874A (ja) 置換ピラゾロ-ピリミジンおよびその使用
CN107108653B (zh) 吡唑并噻唑化合物及医药
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
JPWO2021021986A5 (enExample)
JP2026500715A (ja) 新規ベンズイミダゾール誘導体
TW202412783A (zh) 酪胺酸激酶2抑制劑及其用途
JPWO2021030379A5 (enExample)
TW202415666A (zh) 新穎雜環化合物